References


27. Poole CD, Conway P, Currie CJ. An evaluation of the association between C-reactive protein, the change in C-reactive protein over one year, and all-cause mortality in chronic immune-mediated inflammatory disease managed in UK general practice. Rheumatology 2009;48:78-82.


47. FDA. Food and Drug Administration. (http://www.fda.gov/ohrms/dockets/ac/08/slides/2008-4371s1-02-Roche-core_files/frame.htm)


83. CRAT : Centre de Référence sur les Agents Tératogènes, Hôpital Armand Trousseau, Paris, AP-HP. http://lecrat.org
91. Reo mandations HAS 2009.


113. Peake NJ, Khawaja K, Myers A et al. Interleukin-6 signaling in juvenile idiopathic arthritis is limited by proteolytically cleaved soluble interleukin-6 receptor. Rheumatology 2006;45:1485-89.


117. Nishimoto N, Terao K, Mima T et al. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 2008;112:3959-64.


